子宮筋腫治療の世界市場レポート 2025年

子宮筋腫治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で64億6,000万米ドルに成長します。予測期間の成長は、非侵襲的治療の進歩、妊孕性温存の重視の高まり、低侵襲技術の台頭、個別化医療アプローチ、共同研究開発に起因すると考えられます。予測期間の主な動向としては、妊孕性温存治療への注目の高まり、治療計画における画像技術の統合、認知・教育イニシアティブの増加、患者プロファイルに基づくカスタマイズ治療計画、新規治療ターゲットの探索などが挙げられます。

子宮筋腫治療市場の成長が予想される背景には、女性における子宮筋腫の有病率の高さがあります。子宮筋腫は子宮にできる非がん性の腫瘍で、月経時の大量出血、骨盤痛、膀胱や腸の圧迫などの症状を引き起こす可能性があります。子宮筋腫治療では、エストロゲンとプロゲステロンの産生を阻害し、月経を止め、貧血を改善します。例えば、2022年11月にNational Centre for Biotechnology Informationから発表された報告によると、子宮筋腫の推定発生率は35歳以下の女性で40～60％、50歳以上の女性で70～80％です。このように、子宮筋腫の世界の蔓延が子宮筋腫治療市場の成長を後押ししています。

予想されるヘルスケア支出の増加が子宮筋腫治療市場を牽引します。ヘルスケア支出とは、国、政府、組織、または個人が特定の時間枠内でヘルスケア関連の商品やサービスに割り当てる総財源を示します。ヘルスケア支出の増加は、子宮動脈塞栓術や磁気共鳴ガイド下集束超音波手術のような低侵襲手技を含む、先進的な子宮筋腫治療オプションの開発と採用を支えています。例えば、2022年のポーランドのヘルスケア支出は2,056億PLN（509億9,000万米ドル）に達し、GDPの6.7％を占め、2021年から約361億PLN（89億5,000万米ドル）の伸びを示しました。したがって、医療支出の増加は子宮筋腫治療市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界子宮筋腫治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の子宮筋腫治療市場：成長率分析
• 世界の子宮筋腫治療市場の実績：規模と成長, 2019-2024
• 世界の子宮筋腫治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界子宮筋腫治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の子宮筋腫治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 漿膜下筋腫
• 壁内子宮筋腫
• 粘膜下筋腫
• 有茎性子宮筋腫
• 世界の子宮筋腫治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• アンドロゲン
• ゴナドトロピン放出ホルモン拮抗薬
• 子宮動脈塞栓術
• 子宮筋腫摘出術
• 子宮摘出
• 世界の子宮筋腫治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• その他のエンドユーザー
• 世界の子宮筋腫治療市場漿膜下筋腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 有茎性漿膜下筋腫
• 非有茎性漿膜下筋腫
• 世界の子宮筋腫治療市場、筋層内筋腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小さな壁内筋腫
• 大きな筋層内筋腫
• 世界の子宮筋腫治療市場粘膜下線維腫の種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 有茎性粘膜下線維腫
• 非有茎性粘膜下線維腫
• 世界の子宮筋腫治療市場有茎性筋腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 漿膜下有茎性筋腫
• 粘膜下有茎性筋腫

第7章 地域別・国別分析

• 世界の子宮筋腫治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の子宮筋腫治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 子宮筋腫治療市場：競合情勢
• 子宮筋腫治療市場：企業プロファイル
  • Gynesonics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Karl Storz GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbvie Inc.
• Richard Wolf GmbH
• CooperSurgical Inc.
• Olympus Corporation
• Myovant Sciences GmbH
• Insightec Ltd.
• Hologic Inc.
• Obseva SA
• Eli Lilly and Company
• GlaxoSmithKline plc
• Stryker Corporation
• Smith & Nephew plc
• Minerva Surgical Inc.
• Ethicon Inc.
• Cook Medical LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 子宮筋腫治療市場2029：新たな機会を提供する国
• 子宮筋腫治療市場2029：新たな機会を提供するセグメント
• 子宮筋腫治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Uterine fibroids treatment encompasses procedures aimed at addressing uterine fibroids, which are non-cancerous growths that form in the uterus, potentially leading to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel.

The primary categories of uterine fibroids treatment consist of subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids. Subserosal fibroids, also known as pedunculated fibroids, are benign growths located on the outer uterine wall, directly connected to the uterus. Various treatment options are available, including hormone therapy, androgens, gonadotropin-releasing hormone antagonists, uterine artery embolization, myomectomy, and hysterectomy. These treatments cater to diverse end-users such as hospitals, ambulatory surgical centers, and others.

The uterine fibroid treatment market research report is one of a series of new reports from The Business Research Company that provides uterine fibroid treatment market statistics, including uterine fibroid treatment industry global market size, regional shares, competitors with a uterine fibroid treatment market share, detailed uterine fibroid treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid treatment industry. This uterine fibroid treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The uterine fibroids treatment market size has grown strongly in recent years. It will grow from$4.06 billion in 2024 to $4.44 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increased incidence of uterine fibroids, advancements in diagnostic techniques, rising awareness and education, impact on quality of life, evolution of minimally invasive procedures

The uterine fibroids treatment market size is expected to see strong growth in the next few years. It will grow to $6.46 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in non-invasive treatment, increasing emphasis on fertility preservation, rise in minimally invasive techniques, personalized medicine approaches, collaborative research and development. Major trends in the forecast period include rising focus on fertility-preserving treatments, integration of imaging technologies in treatment planning, increasing awareness and education initiatives, customized treatment plans based on patient profiles, exploration of novel therapeutic targets.

The anticipated growth in the uterine fibroids treatment market is attributed to the high prevalence of uterine fibroids among women. Uterine fibroids, non-cancerous growths in the uterus, can lead to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel. Uterine fibroids treatment involves blocking estrogen and progesterone production, ceasing menstruation, and improving anemia. For example, a November 2022 report from the National Centre for Biotechnology Information revealed an estimated incidence of uterine fibroids ranging from 40 to 60% among women under 35 and 70 to 80% among women over 50. Thus, the widespread prevalence of uterine fibroids worldwide propels the uterine fibroids treatment market's growth.

The expected rise in healthcare expenditure is set to drive the uterine fibroids treatment market. Healthcare expenditure denotes the total financial resources allocated by a country, government, organization, or individual for healthcare-related goods and services within a specific timeframe. Increased healthcare expenditure supports the development and adoption of advanced uterine fibroids treatment options, including minimally invasive procedures such as uterine artery embolization or magnetic resonance-guided focused ultrasound surgery. For instance, in 2022, Poland's healthcare expenditure reached PLN 205.6 billion ($50.99 billion), representing 6.7% of GDP, a growth of about PLN 36.1 billion ($8.95 billion) from 2021. Hence, the escalating healthcare expenditure contributes to the uterine fibroids treatment market's expansion.

Product innovations are emerging as a significant trend in the uterine fibroid treatment market. Companies in this sector are implementing innovative solutions to maintain their competitive edge. For example, in September 2024, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched YSELTY, a new treatment for uterine fibroids that represents a major advancement in women's healthcare. YSELTY provides a non-hormonal treatment option with flexible dosing tailored to individual patient needs, especially for those experiencing severe fibroid symptoms. As a GnRH receptor antagonist, YSELTY works by inhibiting gonadotropin-releasing hormone at its pituitary receptors, thereby reducing estrogen production and effectively alleviating symptoms like bleeding and pain.

Significant players in the uterine fibroids treatment market are directing their efforts toward developing minimally invasive procedures (MIPs) for addressing uterine fibroids. Minimally invasive procedures involve medical interventions or surgeries that cause minimal disruption to the body's normal structure and function. These procedures aim to alleviate symptoms such as heavy menstrual bleeding and pelvic pain while reducing recovery times and preserving reproductive options. As an illustration, Humber River Hospital in Canada launched the use of the Acessa ProVu system in November 2022. This medical technology employs monopolar radiofrequency (RF) energy through a disposable Handpiece for percutaneous, laparoscopic coagulation, and ablation of soft tissue, including the treatment of symptomatic uterine fibroids.

In January 2022, Hologic Inc., a US-based medical technology company, acquired Acessa Health for $80 million, enhancing Hologic's presence in the gynecological surgical space. Acessa Health, a US-based biotechnology company, specializes in developing minimally invasive, uterine-sparing devices designed to treat women suffering from symptomatic fibroids.

Major companies operating in the uterine fibroids treatment market include Gynesonics Inc., Medtronic plc, Boston Scientific Corporation, Karl Storz GmbH, Pfizer Inc., Abbvie Inc., Richard Wolf GmbH, CooperSurgical Inc., Olympus Corporation, Myovant Sciences GmbH, Insightec Ltd., Hologic Inc., Obseva SA, Eli Lilly and Company, GlaxoSmithKline plc, Stryker Corporation, Smith & Nephew plc, Minerva Surgical Inc., Ethicon Inc., Cook Medical LLC, C.R. Bard Inc., Biomerics LLC, Visionsense Corp., Halt Medical Inc., Acessa Health Inc., Blue Endo, LiNA Medical ApS, Merit Medical Systems Inc., Allergan plc, Astellas Pharma Inc.

North America was the largest region in the uterine fibroids treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine fibroids treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the uterine fibroids treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The uterine fibroids treatment market includes revenues earned by entities by providing medical, surgical, and radiologically guided therapies available as treatments for uterine fibroids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Uterine Fibroids Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on uterine fibroids treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for uterine fibroids treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uterine fibroids treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Subserosal Fibroids; Intramural Fibroids; Submucosal Fibroids; Pedunculated Fibroids
• 2) By Treatment Type: Hormone Therapy; Androgens; Gonadotropin-Releasing Hormone Antagonists; Uterine Artery Embolization; Myomectomy; Hysterectomy
• 3) By End-Users: Hospitals; Ambulatory Surgical Centers; Other End users
• Subsegments:
• 1) By Subserosal Fibroids: Pedunculated Subserosal Fibroids; Non-Pedunculated Subserosal Fibroids
• 2) By Intramural Fibroids: Small Intramural Fibroids; Large Intramural Fibroids
• 3) By Submucosal Fibroids: Pedunculated Submucosal Fibroids; Non-Pedunculated Submucosal Fibroids
• 4) By Pedunculated Fibroids: Subserosal Pedunculated Fibroids; Submucosal Pedunculated Fibroids
• Companies Mentioned: Gynesonics Inc.; Medtronic plc; Boston Scientific Corporation; Karl Storz GmbH; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Uterine Fibroids Treatment Market Characteristics

3. Uterine Fibroids Treatment Market Trends And Strategies

4. Uterine Fibroids Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Uterine Fibroids Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Uterine Fibroids Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Uterine Fibroids Treatment Market Growth Rate Analysis
• 5.4. Global Uterine Fibroids Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Uterine Fibroids Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Uterine Fibroids Treatment Total Addressable Market (TAM)

6. Uterine Fibroids Treatment Market Segmentation

• 6.1. Global Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids
• 6.2. Global Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Therapy
• Androgens
• Gonadotropin-Releasing Hormone Antagonists
• Uterine Artery Embolization
• Myomectomy
• Hysterectomy
• 6.3. Global Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Other End users
• 6.4. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Subserosal Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pedunculated Subserosal Fibroids
• Non-Pedunculated Subserosal Fibroids
• 6.5. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Intramural Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Intramural Fibroids
• Large Intramural Fibroids
• 6.6. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Submucosal Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pedunculated Submucosal Fibroids
• Non-Pedunculated Submucosal Fibroids
• 6.7. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Pedunculated Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subserosal Pedunculated Fibroids
• Submucosal Pedunculated Fibroids

7. Uterine Fibroids Treatment Market Regional And Country Analysis

• 7.1. Global Uterine Fibroids Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Uterine Fibroids Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Uterine Fibroids Treatment Market

• 8.1. Asia-Pacific Uterine Fibroids Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Uterine Fibroids Treatment Market

• 9.1. China Uterine Fibroids Treatment Market Overview
• 9.2. China Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Uterine Fibroids Treatment Market

• 10.1. India Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Uterine Fibroids Treatment Market

• 11.1. Japan Uterine Fibroids Treatment Market Overview
• 11.2. Japan Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Uterine Fibroids Treatment Market

• 12.1. Australia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Uterine Fibroids Treatment Market

• 13.1. Indonesia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Uterine Fibroids Treatment Market

• 14.1. South Korea Uterine Fibroids Treatment Market Overview
• 14.2. South Korea Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Uterine Fibroids Treatment Market

• 15.1. Western Europe Uterine Fibroids Treatment Market Overview
• 15.2. Western Europe Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Uterine Fibroids Treatment Market

• 16.1. UK Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Uterine Fibroids Treatment Market

• 17.1. Germany Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Uterine Fibroids Treatment Market

• 18.1. France Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Uterine Fibroids Treatment Market

• 19.1. Italy Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Uterine Fibroids Treatment Market

• 20.1. Spain Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Uterine Fibroids Treatment Market

• 21.1. Eastern Europe Uterine Fibroids Treatment Market Overview
• 21.2. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Uterine Fibroids Treatment Market

• 22.1. Russia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Uterine Fibroids Treatment Market

• 23.1. North America Uterine Fibroids Treatment Market Overview
• 23.2. North America Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Uterine Fibroids Treatment Market

• 24.1. USA Uterine Fibroids Treatment Market Overview
• 24.2. USA Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Uterine Fibroids Treatment Market

• 25.1. Canada Uterine Fibroids Treatment Market Overview
• 25.2. Canada Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Uterine Fibroids Treatment Market

• 26.1. South America Uterine Fibroids Treatment Market Overview
• 26.2. South America Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Uterine Fibroids Treatment Market

• 27.1. Brazil Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Uterine Fibroids Treatment Market

• 28.1. Middle East Uterine Fibroids Treatment Market Overview
• 28.2. Middle East Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Uterine Fibroids Treatment Market

• 29.1. Africa Uterine Fibroids Treatment Market Overview
• 29.2. Africa Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Uterine Fibroids Treatment Market Competitive Landscape And Company Profiles

• 30.1. Uterine Fibroids Treatment Market Competitive Landscape
• 30.2. Uterine Fibroids Treatment Market Company Profiles
  • 30.2.1. Gynesonics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Karl Storz GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Uterine Fibroids Treatment Market Other Major And Innovative Companies

• 31.1. Abbvie Inc.
• 31.2. Richard Wolf GmbH
• 31.3. CooperSurgical Inc.
• 31.4. Olympus Corporation
• 31.5. Myovant Sciences GmbH
• 31.6. Insightec Ltd.
• 31.7. Hologic Inc.
• 31.8. Obseva SA
• 31.9. Eli Lilly and Company
• 31.10. GlaxoSmithKline plc
• 31.11. Stryker Corporation
• 31.12. Smith & Nephew plc
• 31.13. Minerva Surgical Inc.
• 31.14. Ethicon Inc.
• 31.15. Cook Medical LLC

32. Global Uterine Fibroids Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Uterine Fibroids Treatment Market

34. Recent Developments In The Uterine Fibroids Treatment Market

35. Uterine Fibroids Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Uterine Fibroids Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Uterine Fibroids Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Uterine Fibroids Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer